<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Doxazosin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Doxazosin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Doxazosin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12398" href="/d/html/12398.html" rel="external">see "Doxazosin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="86242" href="/d/html/86242.html" rel="external">see "Doxazosin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F162904"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cardura;</li>
<li>Cardura XL</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866664"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Doxazosin;</li>
<li>JAMP-Doxazosin;</li>
<li>TEVA-Doxazosin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F162945"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alpha <sub>1</sub> Blocker;</li>
<li>
                        Antihypertensive</li></ul></div>
<div class="block doa drugH1Div" id="F162909"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> If therapy is discontinued for several days, begin with initial dose and retitrate as needed due to risk of orthostatic hypotension.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64ef9771-0186-450c-8cac-9fbc347a4341">Benign prostatic hyperplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Benign prostatic hyperplasia (monotherapy or combination therapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients with moderate to severe predominant storage lower urinary tract symptoms, use in combination with beta-3 agonist or anticholinergic agent. In patients with a significantly enlarged prostate (prostate volume &gt;30 mL, prostate-specific antigen &gt;1.5 ng/mL, or palpable prostate enlargement on digital rectal exam), use in combination with 5-alpha reductase inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34384237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34384237'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i>
<b>Oral:</b> Initial: 1 mg once daily in the morning or evening; may titrate by doubling the daily dose (eg, to 2 mg, then 4 mg, then 8 mg) at 1- to 2-week intervals up to 8 mg once daily based on patient response and tolerability; maximum dose: 8 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i>
<b>Oral:</b> 4 mg once daily in the morning; may titrate based on response and tolerability after 3 to 4 weeks to 8 mg once daily; maximum dose: 8 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Conversion to extended release from immediate release: If immediate release is normally taken in the evening, do not administer evening dose. Then start extended-release product the following morning at lowest dose (4 mg once daily) and titrate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Not recommended for initial management but may be considered as additional therapy for resistant hypertension in patients who do not respond adequately to combination therapy with preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i>
<b>Oral: </b>Initial: 1 mg once daily; titrate gradually as needed based on response and tolerability up to a dose of 16 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f22af56-3956-4591-9dca-11295dae391d">Ureteral stone(s) expulsion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ureteral stone(s) expulsion (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in patients with ureteral stones &gt;5 and ≤10 mm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29620795','lexi-content-ref-27908918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29620795','lexi-content-ref-27908918'])">Ref</a></span>). Although most evidence exists for distal ureteral stones, given the low side effect profile of alpha-blockers, may consider use in patients with stones in any location of ureter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27238616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27238616'])">Ref</a></span>). Additionally, may consider for use after shock wave lithotripsy to help pass stone fragments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27238616','lexi-content-ref-33179245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27238616','lexi-content-ref-33179245'])">Ref</a></span>). A uroselective alpha-blocker (eg, tamsulosin) may be preferred to decrease risk of hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34860948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34860948'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i>
<b>Oral:</b> 4 mg once daily in the evening until stone passage or for up to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29620795','lexi-content-ref-21557836','lexi-content-ref-21072591','lexi-content-ref-33493214']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29620795','lexi-content-ref-21557836','lexi-content-ref-21072591','lexi-content-ref-33493214'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991906"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2945688','lexi-content-ref-2139337','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2945688','lexi-content-ref-2139337','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (Carlson 1986): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989144"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild to moderate impairment (Child-Pugh class A or B): There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Severe impairment (Child-Pugh class C): Use is not recommended.</p></div>
<div class="block doe drugH1Div" id="F162910"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Avoid use for hypertension treatment (alternative agents have superior risk-benefit profiles) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F4473154"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="86242" href="/d/html/86242.html" rel="external">see "Doxazosin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>If drug is discontinued for several days, consider beginning with initial dose and retitrate as needed.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f0387dc2-0cca-4a5a-a547-7e0bda0e153a">Dysfunctional voiding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dysfunctional voiding:</b> Limited data available, efficacy results variable: Children ≥3 years and Adolescents: Immediate release: Oral: Initial: 0.5 mg once daily at bedtime; some trials maintained a fixed dose; others titrated at weekly or biweekly intervals to effect as tolerated; maximum daily dose: 2 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10458432','lexi-content-ref-14501648','lexi-content-ref-22196407','lexi-content-ref-16148665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10458432','lexi-content-ref-14501648','lexi-content-ref-22196407','lexi-content-ref-16148665'])">Ref</a></span>). In some trials, a larger initial dose (1 mg/<b>day</b>) was used in patients weighing &gt;40 to 50 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10458432','lexi-content-ref-16148665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10458432','lexi-content-ref-16148665'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Limited data available: <b>Note:</b> Doxazosin is not discussed as a therapeutic option in current guidelines for use in routine treatment of hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Immediate release: Oral: Initial: 1 mg/<b>day</b>; maximum daily dose: 4 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286277','lexi-content-ref-NIH.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286277','lexi-content-ref-NIH.2011'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f22af56-3956-4591-9dca-11295dae391d">Ureteral stone(s) expulsion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ureteral stone(s) expulsion: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: <b>Note:</b> Fixed doses target an initial weight-based dose of approximately 0.03 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23343614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23343614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;25 kg: Immediate release: Oral: 0.5 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726452','lexi-content-ref-19846149','lexi-content-ref-23343614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726452','lexi-content-ref-19846149','lexi-content-ref-23343614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">25 to &lt;43 kg: Immediate release: Oral: 1 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726452','lexi-content-ref-19846149','lexi-content-ref-23343614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726452','lexi-content-ref-19846149','lexi-content-ref-23343614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">43 to 58 kg: Immediate release: Oral: Initial: 1 mg once daily at bedtime; increase to 1.5 mg once daily when initial dose is tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726452','lexi-content-ref-19846149','lexi-content-ref-23343614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726452','lexi-content-ref-19846149','lexi-content-ref-23343614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;58 kg: Immediate release: Oral: Initial: 1 mg once daily at bedtime; increase to 2 mg once daily when initial dose is tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726452','lexi-content-ref-19846149','lexi-content-ref-23343614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726452','lexi-content-ref-19846149','lexi-content-ref-23343614'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51094213"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, limited data suggest renal impairment does not significantly alter pharmacokinetic parameters.</p></div>
<div class="block dohp drugH1Div" id="F51094214"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution and monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling; use is not recommended in adult patients with severe hepatic impairment (Child-Pugh class C).</p></div>
<div class="block arsc drugH1Div" id="F57027830"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Floppy iris syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraoperative floppy iris syndrome </b>(IFIS) has been reported in patients with current or prior use of alpha-1 blockers undergoing cataract surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15899440','lexi-content-ref-17318207','lexi-content-ref-23420297','lexi-content-ref-Herd.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15899440','lexi-content-ref-17318207','lexi-content-ref-23420297','lexi-content-ref-Herd.2007'])">Ref</a></span>). Studies report significantly higher surgical complication rates for patients who experience IFIS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23420297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23420297'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not completely established; may be related to a combination of the pharmacologic action (ie, inhibition of the iris dilator smooth muscle contraction) and long-term smooth muscle atrophy from accumulation in iris pigment epithelial cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29732214','lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29732214','lexi-content-ref-25073735'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may occur with current (within a few days to months of initiation) or prior use (years following discontinuation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25073735','lexi-content-ref-18388959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25073735','lexi-content-ref-18388959'])">Ref</a></span>). A minimum 3-month duration of alpha-1 blocker use has been proposed as a risk for IFIS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18388959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18388959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Individual alpha-1 blocker (risk highest with tamsulosin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Herd.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Herd.2007'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21168223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21168223'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109982'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109982'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Decreased preoperative dilated pupil diameter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109982'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Doxazosin is associated with <b>orthostatic hypotension</b>, which can manifest as <b>dizziness </b>and <b>vertigo</b>; however, some studies suggest that the differences in blood pressure reduction in the standing versus sitting position are not significantly different with use of doxazosin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31327266','lexi-content-ref-Nomura.1996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31327266','lexi-content-ref-Nomura.1996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, inhibition of vascular smooth muscle contraction and vasodilation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19077827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19077827'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; “first dose” orthostatic hypotension may occur 2 to 6 hours after dose. However, has also occurred months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31327266','lexi-content-ref-Nomura.1996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31327266','lexi-content-ref-Nomura.1996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Individual alpha-1 blocker (risk lowest with tamsulosin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10364649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10364649'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• First dose or redose after dose interruption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25073735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid increase in dose</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications that cause orthostatic hypotension (eg, antihypertensives, nitrates, phosphodiesterase-5 inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25073735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females &gt;65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31327266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31327266'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27551761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27551761'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F162876"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Dizziness (≤19%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 1</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, fatigue (≤12%), malaise (≤12%), vertigo (≤16%)<span class="lexi-table-link-container"> (<a aria-label="Vertigo table link" class="lexi-table-link" data-table-id="lexi-content-vertigo" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vertigo')">table 2</a>)</span><span class="table-link" style="display:none;">Vertigo</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:left;">
<b>Doxazosin: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Doxazosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Doxazosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 16 mg once daily in hypertensives and 0.5 to 8 mg once daily in normotensives</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Benign prostatic hyperplasia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">665</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Including vertigo</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 16 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">339</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">336</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 8 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">651</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4 to 8 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">666</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vertigo" frame="border" id="lexi-content-vertigo" rules="all">
<caption style="text-align:left;">
<b>Doxazosin: Adverse Reaction: Vertigo</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Doxazosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Doxazosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 16 mg once daily in hypertensives and 0.5 to 8 mg once daily in normotensives</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Benign prostatic hyperplasia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">665</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Including dizziness</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 8 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">651</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4 to 8 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">666</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (≤3%), hypotension (≤2%), orthostatic hypotension (1% to 2%)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension')">table 3</a>)</span><span class="table-link" style="display:none;">Orthostatic Hypotension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic Hypotension" frame="border" id="lexi-content-orthostatic-hypotension" rules="all">
<caption style="text-align:left;">
<b>Doxazosin: Adverse Reaction: Orthostatic Hypotension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Doxazosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Doxazosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 8 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">651</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4 to 8 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">666</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), dyspepsia (1%), nausea (1% to 2%), xerostomia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (4% to 7%), drowsiness (1% to 5%), headache (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1% to 3%), respiratory tract infection (5%), rhinitis (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, chest pain, palpitations, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, hot flash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, impotence</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hematologic &amp; oncologic: Decreased neutrophils</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, bradycardia (Pigot 2022), cardiac arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia (Viola 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, gastrointestinal obstruction, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria, nocturia, priapism (Avisrror 2000), urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia, purpuric disease, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, cholestatic hepatitis, hepatitis, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Piller 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, cerebrovascular accident (Mansoor 2002), hypoesthesia, myasthenia, nervousness, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, intraoperative floppy iris syndrome (cataract surgery) (Haridas 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Aggravated bronchospasm</p></div>
<div class="block coi drugH1Div" id="F162890"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to doxazosin, other quinazolines (eg, prazosin, terazosin), or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Galactose intolerance, the congenital lactase deficiency or glucose-galactose malabsorption.</p></div>
<div class="block war drugH1Div" id="F162873"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effect: Decreases in WBC and neutrophil count have been reported; WBC and neutrophils returned to normal after discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with heart failure, angina pectoris, or recent acute myocardial infarction (within the last 6 months). If symptoms of angina pectoris appear or worsen, discontinue use. In a scientific statement from the American Heart Association, doxazosin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with mild to moderate impairment (Child-Pugh class A and B); monitor blood pressure and for symptoms of hypotension. Not recommended in severe impairment (Child-Pugh class C) (extensively metabolized).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cataract surgery patients: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha-1 blockers; there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery. May require modifications to surgical technique; instruct patients to inform ophthalmologist of current or previous alpha-1 blocker use when considering eye surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extended release: Consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction. Use caution in patients with increased GI retention (eg, chronic constipation) as doxazosin exposure may be increased.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warning/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Extended release: Not indicated for use in women or for the treatment of hypertension.</p></div>
<div class="block foc drugH1Div" id="F162884"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardura: 1 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardura: 1 mg [DSC], 2 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardura: 2 mg [DSC] [scored; contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardura: 4 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardura: 4 mg [DSC] [scored; contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg, 4 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardura: 8 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardura: 8 mg [DSC] [scored; contains fd&amp;c blue #2 (indigotine,indigo carmine), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 8 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardura XL: 4 mg, 8 mg</p></div>
<div class="block geq drugH1Div" id="F162869"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F162893"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Cardura XL Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $7.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $8.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cardura Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $6.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $6.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $7.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $7.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Doxazosin Mesylate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $1.02 - $1.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.72 - $1.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $1.03 - $1.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $1.49</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866665"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg, 4 mg</p></div>
<div class="block adm drugH1Div" id="F162887"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Swallow tablets whole; do not crush, cut, chew, or divide. Administer with morning meal.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Administer daily dose either in the morning or evening.</p></div>
<div class="block admp drugH1Div" id="F52612627"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Immediate release: Administer without regard to meals at the same time each day.</p></div>
<div class="block use drugH1Div" id="F162886"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Benign prostatic hyperplasia:</b> Treatment of signs and symptoms of benign prostatic hyperplasia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (immediate release only):</b> Management of hypertension. <b>Note:</b> Alpha blockers are not recommended as first-line therapy (ACC/AHA [Whelton 2018]).</p></div>
<div class="block off-label drugH1Div" id="F25725320"><span class="drugH1">Use: Off-Label: Adult</span><p>Ureteral stone(s), expulsion</p></div>
<div class="block mst drugH1Div" id="F162953"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Doxazosin may be confused with doxapram, doxepin, DOXOrubicin</p>
<p style="text-indent:-2em;margin-left:4em;">Cardura may be confused with Cardene, Cordarone, Cordran, Coumadin, K-Dur, Ridaura</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Doxazosin is identified in the Beers Criteria as a potentially inappropriate medication for hypertension in patients 65 years and older due to its high risk of orthostatic hypotension. Avoid use for hypertension treatment (alternative agents have superior risk-benefit profiles) (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299231"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F162878"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Doxazosin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Alpha1-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers (Nonselective). Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58086862"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Doxazosin is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p></div>
<div class="block pri drugH1Div" id="F2931842"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Doxazosin crosses the placenta (Versmissen 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of chronic hypertension during pregnancy is indicated, agents other than doxazosin may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated hypertension due to a pheochromocytoma during pregnancy is associated with a high rate of maternal and fetal mortality; therefore, treatment is recommended (ESC [Cífková 2020]). Case reports describe the use of doxazosin for the treatment of hypertension due to pheochromocytoma or paraganglioma in pregnant patients (Bettencourt 2022; Chu 2020; Giampaolino 2018; van der Weerd 2017). Doxazosin is a recommended option for the treatment of hypertension due to pheochromocytoma during pregnancy (Gruber 2021; Lenders 2019; Pacu 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Although alpha-blockers may be used to facilitate ureteral stone expulsion, treatments other than doxazosin are preferred if stone removal is needed during pregnancy (AUA/ES [Assimos 2016]; Juliebø-Jones 2022; Lee 2021; Lloyd 2016).</p></div>
<div class="block brc drugH1Div" id="F8097533"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Doxazosin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of doxazosin in breast milk are available from a single case report following a maternal dose of doxazosin 4 mg every 24 hours for 2 doses for urinary stones. Milk samples were obtained at various intervals over 24 hours, beginning ~17 hours after the first dose. Maternal serum samples were obtained at nearly the same times, beginning ~1 hour later. The highest serum and milk concentrations of doxazosin were observed ~1 hour after the dose. Using the highest milk concentration (4.15 mcg/L), the estimated dose to the breastfeeding infant was calculated to be &lt;1% of the weight-adjusted maternal dose (Jensen, 2013). In general, breastfeeding is considered acceptable when the relative infant dose of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">In a second case report, doxazosin was not present in breast milk when sampled 30 hours after the last maternal dose. In this case, maternal doxazosin was administered for hypertension due to a pheochromocytoma, surgically removed after delivery. Doxazosin 4 mg once daily was used during pregnancy, increased to 6 mg/day prior to delivery, and 8 mg/day 3 days postpartum prior to being discontinued (Versmissen 2016).</p></div>
<div class="block dic drugH1Div" id="F2932026"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Administer extended-release tablet with morning meal.</p></div>
<div class="block mop drugH1Div" id="F162882"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Benign prostatic hyperplasia:</b> International Prostate Symptom Score (baseline and 4 to 12 weeks after treatment initiation); urinalysis (baseline); objective and subjective signs of relief of benign prostatic hyperplasia and lower urinary tract symptoms (AUA [Lerner 2021]).</p></div>
<div class="block pha drugH1Div" id="F162872"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;text-align:justify;">Hypertension: Competitively inhibits postsynaptic alpha<sub>1</sub>-adrenergic receptors which results in vasodilation of veins and arterioles and a decrease in total peripheral resistance and blood pressure; ~50% as potent on a weight by weight basis as prazosin.</p>
<p style="text-indent:0em;margin-top:2em;text-align:justify;">BPH: Competitively inhibits postsynaptic alpha<sub>1</sub>-adrenergic receptors in prostatic stromal and bladder neck tissues. This reduces the sympathetic tone-induced urethral stricture causing BPH symptoms.</p></div>
<div class="block phk drugH1Div" id="F162889"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: &gt;24 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~98%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic to active metabolites; primarily via CYP3A4; secondary pathways involve CYP2D6 and 2C9</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Immediate release: ~65%; Extended release relative to immediate release: 54% to 59%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Immediate release: ~22 hours; Extended release: 15 to 19 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Immediate release: 2 to 3 hours; Extended release: 8 ±  3.7 to 9 ± 4.7 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (~63%, primarily as metabolites [4.8% as unchanged]); urine (9%, primarily as metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51153983"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Immediate release: 40% increase in exposure in mild impairment (Child-Pugh class A).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Extended release: C<sub>max</sub> and AUC increased 27% and 34% respectively in elderly patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F162894"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Uniprost</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Doxasin | Doxazosina biol | Doxazosina richet | Doxolbran | Lafedoxin | Prostazosina | Vazosin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ascalan | Doxapress | Doxazosin 1a pharma gmbh | Doxazosin actavis | Doxazosin arcana | Doxazosin Genericon | Doxazosin genericon pharma | Doxazosin hexal pharma | Doxazosin ratiopharm | Doxazosin stada | Hibadren | Prostadilat | Supressin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Carduran</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Cardular | Doxacor</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Cardura xl | Doxazosin | Doxazosin aurobindo | Kamiren | Kamiren xl | Zoxon</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Carduran | Doxaneo | Doxaprost | Doxativo | Doxsol | Doxuran | Duomo | Euprostatin | Lutics | Mesidox | Mesilato de doxazosina | Prodil | Pros | Prostaflux | Unoprost | Zoflux</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Doxazosin Helvepharm | Doxazosin retard zentiva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Cardular</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alfadoxin | Angicon | Cardura | Dorbantil | Doxazosina | Duomo</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Beyacin | Cardura xl | Doxazosin mesylate | Duo xi lin | Jin chang | Luo xin ping | Shuang jiang ping | Yi li ping | Zhong wei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Carduran | Carduran xl | Dalgen | Doxaprost | Doxazosina | Prostaride</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Cardura xl | Doxazosin aurobindo | Doxazosin polpharma | Doxazosin teva | Kamiren | Zoxon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alfamedin | Cardular pp | Cardura | Diblocin | Doxa-Puren | Doxacin | Doxacor | Doxagamma | Doxamax | Doxauro | Doxazoflo | Doxazomerck | Doxazosin | Doxazosin Abz | Doxazosin acino | Doxazosin aurobindo | Doxazosin Aurus | Doxazosin azu | Doxazosin dura | Doxazosin Heumann | Doxazosin ratiopharm | Doxazosin stada | Doxazosin Uro 1 A Pharma | Doxazosin-1 A Pharma | Jutalar | Uriduct</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Biozosin | Doxazosin niche generics | Doxazosin pliva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cardulam | Cardura xl | Doxazosin | Doxine | Doxolbran | Hpb</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cardura xl | Dorbantil | Doxazosina | Doxazosina nifa | Doxazoxial</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Cardura xl | Doxalfa | Doxazosin ratiopharm | Doxazosin teva | Doxonex | Kamiren | Zoxon</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Dosin | Doxacor | Doxazin | Doxazosin stada | Duracin | Elaxicopa | Epcura</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Carduran | Carduran neo | Doxatensa | Doxazosina alter | Doxazosina aurobindo | Doxazosina aurovitas | Doxazosina bexal | Doxazosina cinfa | Doxazosina combino | Doxazosina edigen | Doxazosina Merck | Doxazosina neo | Doxazosina neo cinfa | Doxazosina neo mylan pharmaceuticals | Doxazosina Neo Sandoz | Doxazosina neo stada | Doxazosina Neo Teva | Doxazosina normon | Doxazosina pharmagenus | Doxazosina ratiopharm | Doxazosina ur | Progandol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Carduran | Doxazosine Actavis | Doxazosine arrow | Doxazosine mylan | Doxazosine teva | Zoxan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cardozin | Cardura | Cascor | Colixil | Doxacard | Doxadura | Doxazosin | Doxazosin almus | Doxazosin arrow | Doxazosin cox | Doxazosin medreich | Doxazosin sandoz | Larbex | Raporsin | Slocinx xl</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Maguran</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo doxazosin | Cardura | Dophilin | Doxacard | Doxan | Doxasin | Doxasyn | Doxazo | Doxino | Kamiren | Pencor</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Doksazosin Lek | Doxa | Doxazin | Kamiren | Tonocardin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Doxagal | Doxazosin aurobindo | Doxazosin Hexal | Doxazosin ratiopharm | Doxicard | Dozone | Kamiren</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Kaltensif | Tensidox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Carsem | Doxacar | Doxane | Doxatan | Doxel | Kamiren | Raporsin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cadex | Cardoral | Cardura | Doxaloc</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alfazosin | Doxacard | Doxapress | Duracard</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Atensil | Benur | Cardura | Dedralen | Dilur | Doxazosin actavis | Doxazosin Doc | Doxazosin provvisoria | Doxazosina Alm | Doxazosina Angenerico | Doxazosina aurobindo | Doxazosina Eg | Doxazosina Fg | Doxazosina Fidia | Doxazosina Merck | Doxazosina Pensa | Doxazosina Ranbaxy | Doxazosina ratiopharm | Doxazosina Sandoz | Kimura | Noradox | Normothen | Saidox</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Alphapress | Cardox | Cardura | Curcard | Magurol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alflosin | Cademesin | Calmesosyn | Calmesosyn merck hoei | Carbadogen | Cardenalin | Cardonan | Donashin | Doxazon | Doxazosin | Doxazosin Emec | Doxazosin mesilate hexal | Doxazosin Mesilate Jdolph | Doxazosin Mesilate Meiji | Doxazosin Mesilate Taisho | Doxazosin Mesilate Takata | Doxazosin mesilate yoshindo | Doxazosin nichiiko | Kazmarin | Tatsuzosin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Dilur</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bidox | Cadil | Cadlin | Cadoxil | Caduramin | Carbi XL | Cardil | Cardil XL | Cardura | Cardura xl | Caron | Carzora | Carzosin | Cazora | Doxacin | Doxazocin | Doxazon | Doxazosin mesylate hanall | Doxicamin | Genuone doxazosin mesylate | Misadin | Pzocin | Withus doxazosin mesylate</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cardura</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Alphapress | Cardular | Curcard | Noradox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Cardura xl | Doxalfa | Doxazosin actavis | Doxazosin teva | Doxonex | Kamiren | Magurol | Tonocardin | Zoxon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Cardura xl | Doxagamma | Doxalfa | Doxazosin actavis | Doxazosin Hexal | Doxonex | Kamiren | Kamiren xl | Magurol | Zoxon</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Zoxan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Cardura xl | Doxazosina | Xidor</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo doxazosin | Cardura | Kamiren | Magurol | Pencor</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Cardura xl | Doxazosin sandoz</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Cardura xl | Carduran | Doxazosine | Doxazosine cf | Doxazosine merck | Doxazosine mylan | Doxazosine sandoz | Progandol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Alfadil | Cardura | Carduran cr | Doxadura xl | Doxazosin | Doxazosin ct arzneimittel | Doxazosine arrow lp | Doxazosine mylan lp</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo doxazosin | Cardoxan | Dosan | Doxazosin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cardura xl | Dorbantil | Doxazin | Duomo</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alfadil XL | Carduran | Doxazosin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cardia | Cardura | Doxagit | Doxura | Dozax | Proalpha | Prosdura | Uripas</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adadox | Apo-doxan | Cardura | DoxaLEK | Doxalong | Doxanorm | Doxar | Doxaratio | Doxazosin 1 A pharma | Doxazosin aurovita | Doxazosin genoptim | Doxazosin ratiopharm | Doxorion | Dozox | Kamiren | Prostatic | Zoxon</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Doxazosin | Doxazosin mesylate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Doxazosina | Doxazosina arrowblue | Doxazosina Generis</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dorbantil</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cardura</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Doxazosin 1 medochemie | Doxazosin al | Doxazosin arena | Doxazosin sandoz | Dozasin | Kamiren | Zoxon</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Artesin | Artezine | Cardura | Doxaprostan | Doxazosin | Doxazosin belupo | Doxazosin sandoz | Doxazosin zentiva | Kamiren | Kamiren xl | Kardura | Magurol | Urocard | Vero doxazosin | Zoxon</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo doxazosin | Cardura | Doxagen | Uniprost</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Alfadil | Cardura | Carduran | Doxalfa | Doxazosin actavis | Doxazosin arrow | Doxazosin ebb | Doxazosin mylan | Doxazosin ratiopharm | Doxazosin sandoz | Doxazosin stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cardura</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cardosin retard | Cardura xl | Doxazosin arrow | Kamiren | Tonocardin | Tonocardin sr</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Cardura xl | Magurol | Zoxon</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Barova | Cardolin | Cardura | Carduran | Cazosin | Dezcard | Doxapan | Dozozin | Duracard | Genzosin | Lennox | Pencor | Xadosin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cardular</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Doksura | Doxacor | Kardozin | Tendura</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dophilin | Dosabin | Dosabin xl | Doxaben | Doxaben XL | Doxacor | Doxan | Doxazon | Doxazosin | Genlease | Genzosin | Kinxaben | Saxobin | Xadosin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Doxapress | Doxazin | Doxazosin | Doxazosin ratiopharm | Doxonex | Genocard | Kamiren | Magurol | Tonocardin | Uromax | Zoxon</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Dosin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cardura</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cardura | Cardura xl | Doxazosina elter | Doxolbran</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Binexcadil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco-doxazosin | Cardura | Carzin | Urodoxa</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Cardura xl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19077827">
<a name="19077827"></a>Abdel-Aziz S, Mamalis N. Intraoperative floppy iris syndrome. <i>Curr Opin Ophthalmol</i>. 2009;20(1):37-41. doi:10.1097/ICU.0b013e32831bc0ad<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/19077827/pubmed" id="19077827" target="_blank">19077827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [published corrections appearing in <i>Circulation</i>. 2011 Aug 2;124(5):e175; <i>Circulation</i>. 2011 May 31;123(21):e616; <i>Circulation</i>. 2016 Jun 14;133(24):e715]. <i>Circulation</i>. 2011 May 31;123(21):2434-506. doi:10.1161/CIR.0b013e31821daaf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27238616">
<a name="27238616"></a>Assimos D, Krambeck A, Miller NL, et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part I. <i>J Urol</i>. 2016;196(4):1153-1160. doi:10.1016/j.juro.2016.05.090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/27238616/pubmed" id="27238616" target="_blank">27238616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22228043">
<a name="22228043"></a>Ateş F, Eryildirim B, Öztürk MI, et al; AYTAG Group. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. <i>Urol Res</i>. 2012;40(5):537-542. doi:10.1007/s00240-011-0455-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/22228043/pubmed" id="22228043" target="_blank">22228043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10458432">
<a name="10458432"></a>Austin PF, Homsy YL, Masel JL, Cain MP, Casale AJ, Rink RC. alpha-Adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. <i>J Urol</i>. 1999;162(3 Pt 2):1064-1067. doi:10.1097/00005392-199909000-00029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/10458432/pubmed" id="10458432" target="_blank">10458432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10604360">
<a name="10604360"></a>Avisrror MU, Fernandez IA, Sánchez AS, García-Pando AC, Arias LM, del Pozo JG. Doxazosin and priapism. <i>J Urol</i>. 2000;163(1):238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/10604360/pubmed" id="10604360" target="_blank">10604360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19846149">
<a name="19846149"></a>Aydogdu O, Burgu B, Gucuk A, Suer E, Soygur T. Effectiveness of doxazosin in treatment of distal ureteral stones in children. <i>J Urol</i>. 2009;182(6):2880-2884. doi:10.1016/j.juro.2009.08.061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/19846149/pubmed" id="19846149" target="_blank">19846149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35295164">
<a name="35295164"></a>Bettencourt AR, Alves C. Perioperative management of a patient with secreting paraganglioma undergoing cesarean section. <i>Case Rep Anesthesiol</i>. 2022;2022:9065324. doi:10.1155/2022/9065324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/35295164/pubmed" id="35295164" target="_blank">35295164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14501648">
<a name="14501648"></a>Cain MP, Wu SD, Austin PF, Herndon CD, Rink RC. Alpha blocker therapy for children with dysfunctional voiding and urinary retention. <i>J Urol</i>. 2003;170(4 Pt 2):1514-1515; discussion 1516-1517. doi:10.1097/01.ju.0000085961.27403.4a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/14501648/pubmed" id="14501648" target="_blank">14501648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620795">
<a name="29620795"></a>Campschroer T, Zhu X, Vernooij RW, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. <i>Cochrane Database Syst Rev</i>. 2018;4:CD008509. doi:10.1002/14651858.CD008509.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/29620795/pubmed" id="29620795" target="_blank">29620795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cardura.2021.06">
<a name="Cardura.2021.06"></a>Cardura (doxazosin) [prescribing information]. New York, NY: Pfizer; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CarduraXL.2022.04">
<a name="CarduraXL.2022.04"></a>Cardura XL (doxazosin) [prescribing information]. New York, NY: Pfizer; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CarduraXL.2021.06">
<a name="CarduraXL.2021.06"></a>Cardura XL (doxazosin) [prescribing information]. New York, NY: Pfizer; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CarduraCanada.2017.04">
<a name="CarduraCanada.2017.04"></a>Cardura (doxazosin) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada; April 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2945688">
<a name="2945688"></a>Carlson RV, Bailey RR, Begg EJ, Cowlishaw MG, Sharman JR. Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. <i>Clin Pharmacol Ther</i>. 1986;40(5):561-566. doi:10.1038/clpt.1986.224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/2945688/pubmed" id="2945688" target="_blank">2945688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15899440">
<a name="15899440"></a>Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. <i>J Cataract Refract Surg</i>. 2005;31(4):664-673. doi:10.1016/j.jcrs.2005.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/15899440/pubmed" id="15899440" target="_blank">15899440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20171678">
<a name="20171678"></a>Chase J, Austin P, Hoebeke P, McKenna P; International Children's Continence Society. The management of dysfunctional voiding in children: a report from the Standardisation Committee of the International Children's Continence Society. <i>J Urol</i>. 2010;183(4):1296-1302. doi:10.1016/j.juro.2009.12.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/20171678/pubmed" id="20171678" target="_blank">20171678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21168223">
<a name="21168223"></a>Chatziralli IP, Sergentanis TN. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. <i>Ophthalmology</i>. 2011;118(4):730-735. doi:10.1016/j.ophtha.2010.08.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/21168223/pubmed" id="21168223" target="_blank">21168223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32109982">
<a name="32109982"></a>Christou CD, Tsinopoulos I, Ziakas N, Tzamalis A. Intraoperative floppy iris syndrome: Updated perspectives. <i>Clin Ophthalmol</i>. 2020;14:463-471. doi:10.2147/OPTH.S221094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/32109982/pubmed" id="32109982" target="_blank">32109982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32984520">
<a name="32984520"></a>Chu PY, Burks ML, Sólorzano CC, Bao S. Robotic paraganglioma resection in a pregnant patient. <i>AACE Clin Case Rep.</i> 2020;6(5):e197-e200. doi:10.4158/ACCR-2019-0558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/32984520/pubmed" id="32984520" target="_blank">32984520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension.<i> Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8722437">
<a name="8722437"></a>Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack Trial (ALLHAT). ALLHAT Research Group. <i>Am J Hypertens</i>. 1996;9(4 Pt 1):342-360. doi:10.1016/0895-7061(96)00037-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/8722437/pubmed" id="8722437" target="_blank">8722437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17318207">
<a name="17318207"></a>Dhingra N, Rajkumar KN, Kumar V. Intraoperative floppy iris syndrome with doxazosin.<i> Eye (Lond)</i>. 2007;21(5):678-679. doi:10.1038/sj.eye.6702680<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/17318207/pubmed" id="17318207" target="_blank">17318207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10364649">
<a name="10364649"></a>Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. <i>Eur Urol</i>. 1999;36(1):1-13. doi:10.1159/000019919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/10364649/pubmed" id="10364649" target="_blank">10364649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22196407">
<a name="22196407"></a>El-Hefnawy AS, Helmy T, El-Assmy MM, Sarhan O, Hafez AT, Dawaba M. Doxazosin versus tizanidine for treatment of dysfunctional voiding in children: a prospective randomized open-labeled trial. <i>Urology</i>. 2012;79(2):428-433. doi:10.1016/j.urology.2011.10.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/22196407/pubmed" id="22196407" target="_blank">22196407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23726452">
<a name="23726452"></a>Erturhan S, Bayrak O, Sarica K. Reply by the authors. <i>Urology</i>. 2013b;81(6):1381-1382. doi:10.1016/j.urology.2013.02.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/23726452/pubmed" id="23726452" target="_blank">23726452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23343614">
<a name="23343614"></a>Erturhan S, Bayrak O, Sarica K, Seckiner I, Baturu M, Sen H. Efficacy of medical expulsive treatment with doxazosin in pediatric patients. <i>Urology</i>. 2013a;81(3):640-643. doi:10.1016/j.urology.2012.11.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/23343614/pubmed" id="23343614" target="_blank">23343614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3);e20171904. doi:10.1542/peds.2017-1904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29890868">
<a name="29890868"></a>Giampaolino P, Della Corte L, Formisano C, et al. Successful management of a third-trimester pregnancy complicated by pheochromocytoma: case report. <i>Gynecol Endocrinol</i>. 2018;34(12):1016-1018. doi:10.1080/09513590.2018.1480712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/29890868/pubmed" id="29890868" target="_blank">29890868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman MA, Coleman King SM, et al; American Heart Association; American College of Cardiology; Centers for Disease Control and Prevention. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published correction appearing in <i>Hypertension</i>. 2014;63(6):e175]. <i>Hypertension</i>. 2014;63(4):878-885. doi:10.1161/HYP.0000000000000003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33961120">
<a name="33961120"></a>Gruber LM, Young WF Jr, Bancos I. Pheochromocytoma and paraganglioma in pregnancy: a new era. <i>Curr Cardiol Rep</i>. 2021;23(6):60. doi:10.1007/s11886-021-01485-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/33961120/pubmed" id="33961120" target="_blank">33961120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21557836">
<a name="21557836"></a>Gurbuz MC, Polat H, Canat L, Kilic M, Caskurlu T. Efficacy of three different alpha 1-adrenergic blockers and hyoscine N-butylbromide for distal ureteral stones. <i>Int Braz J Urol</i>. 2011;37(2):195-200. doi:10.1590/s1677-55382011000200006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/21557836/pubmed" id="21557836" target="_blank">21557836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23420297">
<a name="23420297"></a>Haridas A, Syrimi M, Al-Ahmar B, Hingorani M. Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin-a UK-based comparison of incidence and complication rates. <i>Graefes Arch Clin Exp Ophthalmol</i>. 2013;251(6):1541-1545. doi:10.1007/s00417-013-2260-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/23420297/pubmed" id="23420297" target="_blank">23420297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11725558">
<a name="11725558"></a>Hasegawa K. Effect of doxazosin on postural changes in blood pressure using a multibiomedical recorder [in Japanese]. <i>Nihon Jinzo Gakkai Shi</i>. 2001;43(7):600-607.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/11725558/pubmed" id="11725558" target="_blank">11725558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Herd.2007">
<a name="Herd.2007"></a>Herd MK. Intraoperative floppy-iris syndrome with doxazosin. <i>J Cataract Refractive Surgery</i>. 2007;33(4):562. doi:10.1016/j.jcrs.2006.11.019 https://journals.lww.com/jcrs/Fulltext/2007/04000/Intraoperative_floppy_iris_syndrome_with_doxazosin.5.aspx
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31327266">
<a name="31327266"></a>Hiremath S, Ruzicka M, Petrcich W, et al. Alpha-blocker use and the risk of hypotension and hypotension-related clinical events in women of advanced age. <i>Hypertension</i>. 2019;74(3):645-651. doi:10.1161/HYPERTENSIONAHA.119.13289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/31327266/pubmed" id="31327266" target="_blank">31327266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27908918">
<a name="27908918"></a>Hollingsworth JM, Canales BK, Rogers MA, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. <i>BMJ</i>. 2016;355:i6112. doi:10.1136/bmj.i6112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/27908918/pubmed" id="27908918" target="_blank">27908918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women [published correction appearing in <i>N Engl J Med.</i> 2000;343(18):1348]. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [published correction appearing in <i>JAMA</i>. 2014;311(17):1809]. <i>JAMA</i>. 2014;311(5):507-520. doi:10.1001/jama.2013.284427<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439864">
<a name="23439864"></a>Jensen BP, Dalrymple JM, Begg EJ. Transfer of doxazosin into breast milk [published correction appearing in <i>J Hum Lact</i>. 2014;30(3):NP3-NP4]. <i>J Hum Lact</i>. 2013;29(2):150-153. doi:10.1177/0890334412473203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/23439864/pubmed" id="23439864" target="_blank">23439864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36197640">
<a name="36197640"></a>Juliebø-Jones P, Somani BK, Baug S, Beisland C, Ulvik Ø. Management of kidney stone disease in pregnancy: a practical and evidence-based approach. <i>Curr Urol Rep. </i>2022;23(11):263-270. doi:10.1007/s11934-022-01112-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/36197640/pubmed" id="36197640" target="_blank">36197640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34860948">
<a name="34860948"></a>Koski RR, Zufall WH. Efficacy and safety of alpha-blockers for kidney stones in adults. <i>J Pharm Technol</i>. 2018;34(2):54-61. doi:10.1177/8755122517750398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/34860948/pubmed" id="34860948" target="_blank">34860948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35028309">
<a name="35028309"></a>Lee MS, Fenstermaker MA, Naoum EE, et al. Management of nephrolithiasis in pregnancy: multi-disciplinary guidelines from an academic medical center.<i> Front Surg.</i> 2021;8:796876. doi:10.3389/fsurg.2021.796876<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/35028309/pubmed" id="35028309" target="_blank">35028309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31345526">
<a name="31345526"></a>Lenders JWM, Langton K, Langenhuijsen JF, Eisenhofer G. Pheochromocytoma and pregnancy. <i>Endocrinol Metab Clin North Am</i>. 2019;48(3):605-617. doi:10.1016/j.ecl.2019.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/31345526/pubmed" id="31345526" target="_blank">31345526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. <i>J Urol.</i> 2021;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26482104">
<a name="26482104"></a>Lloyd GL, Lim A, Hamoui N, Nakada SY, Kielb SJ. The use of medical expulsive therapy during pregnancy: a worldwide perspective among experts. <i>J Endourol</i>. 2016;30(3):354-358. doi:10.1089/end.2015.0587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/26482104/pubmed" id="26482104" target="_blank">26482104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29732214">
<a name="29732214"></a>Lunacek A, Mohamad Al-Ali B, Radmayr C, et al. Ten years of intraoperative floppy iris syndrome in the era of α-blockers. <i>Cent European J Urol</i>. 2018;71(1):98-104. doi:10.5173/ceju.2017.1234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/29732214/pubmed" id="29732214" target="_blank">29732214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10789664">
<a name="10789664"></a>Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group [published correction appearing in <i>JAMA</i> 2002;288(23):2976]. <i>JAMA</i>. 2000;283(15):1967-1975.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/10789664/pubmed" id="10789664" target="_blank">10789664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11837346">
<a name="11837346"></a>Mansoor GA, Tendler BE. Stroke associated with alpha blocker therapy for benign prostatic hypertrophy. <i>J Natl Med Assoc</i>. 2002;94(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/11837346/pubmed" id="11837346" target="_blank">11837346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14681504">
<a name="14681504"></a>McConnell JD, Roehrborn CG, Bautista OM, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. <i>N Engl J Med</i>. 2003;349(25):2387-2398. doi:10.1056/NEJMoa030656<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/14681504/pubmed" id="14681504" target="_blank">14681504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2011">
<a name="NIH.2011"></a>National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011, National Institutes of Health. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2004;114(2 Suppl 4th Report):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2019">
<a name="NICE.2019"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. https://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nomura.1996">
<a name="Nomura.1996"></a>Nomura A, Kakinoki S, Sakurai M, et al. Effects of doxazosin on orthostatic blood pressure in hypertensive patients with and without diabetes mellitus. <i>Current Therapeutic Res</i>. 1996;57(6):411-417. https://doi.org/10.1016/S0011-393X(96)80049-X
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25073735">
<a name="25073735"></a>Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. <i>Expert Opin Drug Saf</i>. 2014;13(9):1187-97. doi:10.1517/14740338.2014.936376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/25073735/pubmed" id="25073735" target="_blank">25073735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33179245">
<a name="33179245"></a>Oestreich MC, Vernooij RW, Sathianathen NJ, et al. Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults. <i>Cochrane Database Syst Rev</i>. 2020;11(11):CD013393. doi:10.1002/14651858.CD013393.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/33179245/pubmed" id="33179245" target="_blank">33179245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2139337">
<a name="2139337"></a>Oliver RM, Upward JW, Dewhurst AG, Honeywell R, Renwick AG, Waller DG. The pharmacokinetics of doxazosin in patients with hypertension and renal impairment. <i>Br J Clin Pharmacol</i>. 1990;29(4):417-422. doi:10.1111/j.1365-2125.1990.tb03659.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/2139337/pubmed" id="2139337" target="_blank">2139337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34630699">
<a name="34630699"></a>Pacu I, Zygouropoulos N, Furau CG, et al. Pheochromocytoma as a rare hypertensive complication rarely associated with pregnancy: diagnostic difficulties (review). <i>Exp Ther Med.</i> 2021;22(5):1345. doi:10.3892/etm.2021.10780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/34630699/pubmed" id="34630699" target="_blank">34630699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69. doi:10.1161/CIR.0000000000000426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27551761">
<a name="27551761"></a>Paśko P, Rodacki T, Domagała-Rodacka R, Owczarek D. Interactions between medications employed in treating benign prostatic hyperplasia and food - A short review. <i>Biomed Pharmacother</i>. 2016;83:1141-1145. doi:10.1016/j.biopha.2016.08.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/27551761/pubmed" id="27551761" target="_blank">27551761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33547140">
<a name="33547140"></a>Pigot JE, Szeto MCH. Unexpected bradycardia after a first dose of doxazosin. <i>Postgrad Med J</i>. 2022;98(1161):e17. doi:10.1136/postgradmedj-2020-138434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/33547140/pubmed" id="33547140" target="_blank">33547140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16957427">
<a name="16957427"></a>Piller LB, Ford CE, Davis BR, et al. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>J Clin Hypertens (Greenwich)</i>. 2006;8(9):649-658. doi:10.1111/j.1524-6175.2006.05689.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/16957427/pubmed" id="16957427" target="_blank">16957427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15636433">
<a name="15636433"></a>Pulcrano M, Palmieri EA, Pagano L, et al. Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning paraganglioma. <i>J Endocrinol Invest.</i> 2004;27(8):774-777. doi:10.1007/BF03347522<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/15636433/pubmed" id="15636433" target="_blank">15636433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21072591">
<a name="21072591"></a>Resorlu B, Bozkurt OF, Senocak C, Unsal A. Effectiveness of doxazosin in the management of lower ureteral stones in male and female patients. <i>Int Urol Nephrol</i>. 2011;43(3):645-649. doi:10.1007/s11255-010-9867-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/21072591/pubmed" id="21072591" target="_blank">21072591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi:10.1016/j.jash.2015.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15960647">
<a name="15960647"></a>Seefelder C, Sparks JW, Chirnomas D, et al. Perioperative management of a child with severe hypertension from a catecholamine secreting neuroblastoma. <i>Paediatr Anaesth</i>. 2005;15(7):606-610. doi:10.1111/j.1460-9592.2005.01631.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/15960647/pubmed" id="15960647" target="_blank">15960647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18388959">
<a name="18388959"></a>Shah N, Tendulkar M, Brown R. Should we anticipate intraoperative floppy iris syndrome (IFIS) even with very short history of tamsulosin? <i>Eye (Lond)</i>. 2009;23(3):740. doi:10.1038/eye.2008.95<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/18388959/pubmed" id="18388959" target="_blank">18388959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28381449">
<a name="28381449"></a>van der Weerd K, van Noord C, Loeve M, et al. ENDOCRINOLOGY IN PREGNANCY: Pheochromocytoma in pregnancy: case series and review of literature. <i>Eur J Endocrinol</i>. 2017;177(2):R49-R58. doi:10.1530/EJE-16-0920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/28381449/pubmed" id="28381449" target="_blank">28381449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27194370">
<a name="27194370"></a>Versmissen J, Koch BC, Roofthooft DW, et al. Doxazosin treatment of phaeochromocytoma during pregnancy: placental transfer and disposition in breast milk. <i>Br J Clin Pharmacol</i>. 2016;82(2):568-569. doi:10.1111/bcp.12981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/27194370/pubmed" id="27194370" target="_blank">27194370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24888880">
<a name="24888880"></a>Viola E, Opri S, Moretti U, et al. α1-Adrenergic receptor antagonists and gynecomastia. A case series from the Italian spontaneous reporting system and VigiBase(™). <i>Eur J Clin Pharmacol</i>. 2014;70(8):1003-1009. doi:10.1007/s00228-014-1700-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/24888880/pubmed" id="24888880" target="_blank">24888880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26. doi:10.1111/jch.12237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133354">
<a name="29133354"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/29133354/pubmed" id="29133354" target="_blank">29133354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33493214">
<a name="33493214"></a>Yu B, Zheng X, Sun Z, et al. The safety and efficacy of doxazosin in medical expulsion therapy for distal ureteric calculi: a meta-analysis. <i>PLoS One</i>. 2021;16(1):e0245741. doi:10.1371/journal.pone.0245741<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/33493214/pubmed" id="33493214" target="_blank">33493214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16148665">
<a name="16148665"></a>Yucel S, Akkaya E, Guntekin E, et al. Can alpha-blocker therapy be an alternative to biofeedback for dysfunctional voiding and urinary retention? A prospective study. <i>J Urol</i>. 2005;174(4 Pt 2):1612-1615; discussion 1615. doi:10.1097/01.ju.0000179241.99381.5e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/16148665/pubmed" id="16148665" target="_blank">16148665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20189226">
<a name="20189226"></a>Zehri AA, Ather MH, Abbas F, Biyabani SR. Preliminary study of efficacy of doxazosin as a medical expulsive therapy of distal ureteric stones in a randomized clinical trial. <i>Urology</i>. 2010;75(6):1285-1288. doi:10.1016/j.urology.2009.10.069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/20189226/pubmed" id="20189226" target="_blank">20189226</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9389 Version 508.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
